Lincoln Pharmaceuticals Ltd
₹654.30
(6.25%)
Sat, 14 Feb 2026, 00:23 am
Health Technology
Pharmaceuticals: Major
24.5KLincoln Pharmaceuticals Price to Sales Ratio (P/S)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 11.74 | 8.58 | 6.35 | 3.78 | 6.69 | 8.26 | 8.14 | 4.05 | 6.39 | 8.52 | 11.10 | 15 | 12.15 | 8.73 | 5.20 | 7.23 | 8.98 | 9.31 | 12.57 | 13.42 |
| Price to book ratio | 1.14 | 1.08 | 0.92 | 0.44 | 0.77 | 0.74 | 0.52 | 0.44 | 0.69 | 1.15 | 1.82 | 2.45 | 1.88 | 1.58 | 0.85 | 1.23 | 1.44 | 1.35 | 1.98 | 1.64 |
| Price to sales ratio | 0.55 | 0.41 | 0.34 | 0.14 | 0.32 | 0.26 | 0.24 | 0.21 | 0.33 | 0.49 | 0.66 | 1.20 | 1.18 | 1.19 | 0.71 | 1.08 | 1.33 | 1.34 | 2.05 | 1.79 |
| Price to cash flow ratio | 0 | 13.03 | 2.89 | 10.53 | 0 | 0 | 9.05 | 7.11 | 0 | 6.74 | 7.61 | 21.19 | 22.80 | 8.68 | 3.57 | 6.42 | 8.02 | 17.47 | 16.53 | 11.63 |
| Enterprise value | 404.08M | 375.59M | 393.53M | 270.78M | 571.82M | 791.19M | 981.24M | 1.04B | 1.29B | 1.96B | 3.28B | 4.65B | 4.57B | 4.33B | 2.24B | 3.56B | 5.09B | 5.55B | 10.21B | 9.09B |
| Enterprise value to EBITDA ratio | 9.66 | 6.02 | 4.19 | 2.85 | 4.76 | 7.95 | 9.22 | 8.34 | 7.35 | 9.03 | 7.85 | 12.31 | 9.54 | 7.27 | 3.86 | 4.47 | 5.41 | 6.37 | 10.88 | 9.39 |
| Debt to equity ratio | 0.44 | 0.47 | 0.41 | 0.43 | 0.56 | 0.55 | 0.85 | 0.85 | 0.69 | 0.69 | 0.56 | 0.34 | 0.27 | 0.12 | 0.02 | 0 | 0 | 0 | 0 | 0 |
| Return on equity % | 11.26 | 11.04 | 15.35 | 12.43 | 13.61 | 8.99 | 6.50 | 11.36 | 11.33 | 14.29 | 18.81 | 16.90 | 16.71 | 19.74 | 17.66 | 18.32 | 17.16 | 15.59 | 17.04 | 13.02 |
Lincoln Pharmaceuticals Ltd Price to Sales Ratio
The Lincoln Pharmaceuticals Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Lincoln Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Lincoln Pharmaceuticals Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Lincoln Pharmaceuticals Ltd (NSE: LINCOLN, BSE: 531633) is currently trading at ₹654.30, with a market capitalization of ₹12.29B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Lincoln Pharmaceuticals Ltd Price to Sales Ratio is essential for fundamental analysis.
Lincoln Pharmaceuticals Ltd Price to Sales Ratio Current Value
The current Lincoln Pharmaceuticals Ltd Price to Sales Ratio stands at 1.79.
The Lincoln Pharmaceuticals Ltd Price to Sales Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Lincoln Pharmaceuticals Ltd Price to Sales Ratio Historical Trend
The Lincoln Pharmaceuticals Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 1.79
- 2023: 2.05
- 2022: 1.34
- 2021: 1.33
- 2020: 1.08
The decline in Lincoln Pharmaceuticals Ltd Price to Sales Ratio indicates improving financial efficiency or better earnings growth.
What Lincoln Pharmaceuticals Ltd Price to Sales Ratio Indicates for Investors
The Lincoln Pharmaceuticals Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Lincoln Pharmaceuticals Ltd Price to Sales Ratio Analysis Summary
The Lincoln Pharmaceuticals Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Lincoln Pharmaceuticals Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Lincoln Pharmaceuticals Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800